Losartan versus enalapril in the reduction of left ventricular hypertrophy secondary to systemic arterial hypertension;Losartan versus enalapril en la reducción de la hipertrofia ventricular izquierda secundaria a hipertensión arterial sistémica

Archivos de Cardiologia de Mexico

Volumn 74, Issue 3, 2004, Pages 192-199

  Uribe Flores, Jesús Daniel ^a,b,c   Hernández Jácome, Mercedes ^a,b   Guevara Dondé, Jaime ^a   Segura, Xóchitl ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b UNIVERSIDAD VERACRUZANA   (Mexico)

^c NONE   (Mexico)

Author keywords

Enalapril; Left ventricular hypertrophy; Losartan; Systemic arterial hypertension

Indexed keywords

ENALAPRIL; LOSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 9644281564     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. FROHLICH ED: Mechanisms of risk in hypertensive heart disease. Hypertension 1999; 34: 782-789.
2. FROHLICH ED: Current clinical pathophysiologic considerations in essential hypertension. Med Clin North Am 1997; 81: 1113-1129.
3. CARRETERO OA, OPARIL S: Essential hypertension. Part I: definition and etiology. Circulation 2000; 101: 329-335.
4. MESSERLI FH, ARÍSTIZABAL D, SORIA F: Reduction of left ventricular hypertrophy: how beneficial? Am Heart J 1993; 125: 1520-1524.
5. MORGAN HE, BAKER KM: Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation 1991; 83: 13-25.
6. DEVEREUX RB, REICHEK N: Echocardiographic determination of left ventricular mass in man: anatomic validation of method. Circulation 1977; 55: 613-618.
7. LIEBSON PR, SAVAGE DD: Echocardiography in hypertension: a review. Echocardiography 1986; 3: 181-213.
8. DEVEREUX RB, LUTAS EM, CASALE PN: Standardization of M- mode echocardiographic left ventricular measurements. J Am Coll Cardiol 1984; 4: 1222-1230.
9. COCA A, GINER V: Antihypertensive advantages of angiotensin II AT1 receptor antagonism. Rev Esp Cardiol 1999; 5: 53-58.
10. SCHMIEDER RE, MARTUS P, KLINGBEIL A: Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
11. FROHLICH ED: Is reversal of left ventricular hypertrophy in hypertension beneficial. Hypertension 1991; 18: 133-138.
12. DAHLOF B, PENNERT K, HANSSON L: Regression of left ventricular hypertrophy: a meta-analysis. Clin Exp Hypertens 1992; 14: 173-180.
13. DEVEREUX RB: Therapeutic options in minimizing left ventricular hypertrophy. Am Heart J 2000; 139: S9-S14.
14. DEVEREUX RB: Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy. Circulation 1997; 95: 1983-1985.
15. DEVEREUX RB, DAHLOF B, LEVY D: Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1996; 78: 61-65.
16. KONSTAM MA, PATTEN RD, THOMAS I: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000; 139: 1081-1087.
17. LIÈVRE M, GUÉRET P, GAYET C, ROUDAUT R, HAUGH MC, DELAIR S: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92-97.
18. CARRETERO OA, OPARIL S: Essential hypertension. Part II. Treatment. Circulation 2000; 101: 446-453.
19. TIKKANEN I, OMVIK P, JENSEN HE: Comparison of the angiotensin II antagonism losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertension 1995; 13: 1343-1351.
20. DEVEREUX RB, DAHLÖF B: Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens 1994; 8: 735-739.
21. MALMQVIST K, KAHAN T, EDNER M, HELD C, HAGG A, LIND L: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-1176.
22. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National Institutes of Health. USA 1997.
23. AZIZI M, GUYENE TT, CHATELLER G, MÉNARD J: Pharmacological demonstration of the additive effects of angiotensin-convening enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exp Hypertension 1997; 19: 937-51.
24. AZIZI M, GUYENE TT, CHATELLIER G, WARGON M, MENARD J: Additive effects of losartan and enalapril on blood pressure and plasma active rennin. Hypertension 1997; 29: 634-40.
25. GOTTDIENER JS, REDA DJ, MASSIE BM: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007-2014.
26. RUFF D, GAZDICK LP, BERMAN R: Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist or enalapril maleate for the treatment of severe hypertension. J Hypertension 1996; 14: 263-270.
27. BURNIER M, WAEBER B, BRUNNER HR: The advantages of angiotensin II antagonism. J Hypertens 1994; 12: 57-65.
28. BAKER KM, CHERIN MI, WIXON SK: Renin angiotensin system involvement in pressure- overload cardiac hypertrophy in rats. Am J Physiol 1990; 259: 324-332.